Consenso de leucemia mieloide aguda en México / Mexican consensus in acute myeloid leukemia in Mexico
Gac. méd. Méx
; 158(spe): M1-M51, ene. 2022. tab, graf
Article
in Es
|
LILACS-Express
| LILACS
| ID: biblio-1375542
Responsible library:
MX1.1
RESUMEN
resumen está disponible en el texto completo
ABSTRACT
Abstract Acute myeloid leukemia (AML) comprises a heterogeneous group of hematopoietic cell neoplasms of myeloid lineage that arise from the clonal expansion of their precursors in the bone marrow, interfering with cell differentiation, leading to a syndrome of bone marrow failure. AML is a consequence of genetic and epigenetic changes (point mutations, gene rearrangements, deletions, amplifications, and arrangements in epigenetic changes that influence gene expression) in hematopoietic precursor cells, which create a clone of abnormal cells that are capable of proliferating but cannot differentiate into mature hematopoietic cells or undergo programmed cell death. The diagnosis requires more than 20% myeloid blasts in the bone marrow and certain cytogenic abnormalities. Treatment will depend on age, comorbidities, and cytogenetic risk among the most frequent.
Full text:
1
Index:
LILACS
Country/Region as subject:
Mexico
Language:
Es
Journal:
Gac. méd. Méx
Journal subject:
MEDICINA
Year:
2022
Type:
Article